Hasil Pencarian - Jerzy Pieczykolan

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. <em>Int. J. Mol. Sci.</em> 2017, <em>18</em>, 401

    Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. <em>Int. J. Mol. Sci.</em> 2017, <em>18</... oleh Anna M. Serwotka-Suszczak, Alicja M. Sochaj-Gregorczyk, Jerzy Pieczykolan, Daniel Krowarsch, Filip Jelen, Jacek Otlewski

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

    A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells oleh Anna M. Serwotka-Suszczak, Alicja M. Sochaj-Gregorczyk, Jerzy Pieczykolan, Daniel Krowarsch, Filip Jelen, Jacek Otlewski

    Diterbitkan 2017-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

    Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey. oleh Katarzyna Bazydlo-Guzenda, Pawel Buda, Mateusz Mach, Jerzy Pieczykolan, Izabela Kozlowska, Michal Janiszewski, Ewa Drzazga, Jakub Dominowski, Hubert Ziolkowski, Maciej Wieczorek, Shayne Cox Gad

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.

    Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma. oleh Paweł Gunerka, Kamila Gala, Martyna Banach, Jakub Dominowski, Joanna Hucz-Kalitowska, Krzysztof Mulewski, Agnes Hajnal, Endre G Mikus, Damian Smuga, Marcin Zagozda, Krzysztof Dubiel, Jerzy Pieczykolan, Beata M Zygmunt, Maciej Wieczorek

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects

    A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects oleh Mikolaj Matloka, Sylwia Janowska, Piotr Pankiewicz, Sofiya Kokhanovska, Tomasz Kos, Małgorzata Hołuj, Izabela Rutkowska-Wlodarczyk, Krzysztof Abramski, Monika Janicka, Piotr Jakubowski, Maciej Świątkiewicz, Marlena Welniak-Kaminska, Joanna Hucz-Kalitowska, Paulina Dera, Lukasz Bojarski, Paweł Grieb, Piotr Popik, Maciej Wieczorek, Jerzy Pieczykolan

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists

    Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists oleh Piotr Pankiewicz, Marcin Szybiński, Katarzyna Kisielewska, Filip Gołębiowski, Patryk Krzemiński, Izabela Rutkowska-Włodarczyk, Rafał Moszczyński-Pętkowski, Lidia Gurba-Bryśkiewicz, Monika Delis, Krzysztof Mulewski, Damian Smuga, Jakub Dominowski, Artur Janusz, Michał Górka, Krzysztof Abramski, Agnieszka Napiórkowska, Marcin Nowotny, Krzysztof Dubiel, Katarzyna Kalita, Maciej Wieczorek, Jerzy Pieczykolan, Mikołaj Matłoka

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

    Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer oleh Delfina Popiel, Aleksandra Stańczak, Monika Skupińska, Agata Mikołajczyk, Paulina Stańczak, Filip Mituła, Joanna Hucz-Kalitowska, Kinga Jastrzębska, Damian Smuga, Jakub Dominowski, Monika Delis, Krzysztof Mulewski, Wojciech Pietruś, Daria Zdżalik-Bielecka, Karolina Dzwonek, Monika Lamparska-Przybysz, Abdellah Yamani, Patrycja Olejkowska, Natalia Piórkowska, Krzysztof Dubiel, Maciej Wieczorek, Maciej Wieczorek, Jerzy Pieczykolan

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Design, Synthesis, and Development of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as a Novel Series of Selective PI3K<i>δ</i> Inhibitors: Part II—Benzimidazole Derivatives

    Design, Synthesis, and Development of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as a Novel Series of Selective PI3K<i>δ</i> Inhibitors: Part II—Benzimidazole Derivatives oleh Mariola Stypik, Stanisław Michałek, Nina Orłowska, Marcin Zagozda, Maciej Dziachan, Martyna Banach, Paweł Turowski, Paweł Gunerka, Daria Zdżalik-Bielecka, Aleksandra Stańczak, Urszula Kędzierska, Krzysztof Mulewski, Damian Smuga, Wioleta Maruszak, Lidia Gurba-Bryśkiewicz, Arkadiusz Leniak, Wojciech Pietruś, Zbigniew Ochal, Mateusz Mach, Beata Zygmunt, Jerzy Pieczykolan, Krzysztof Dubiel, Maciej Wieczorek

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: